Names | |
---|---|
IUPAC name
O1,O7-Di(5′-deoxyuridin-5′-yl) tetrahydrogen tetraphosphate
| |
Systematic IUPAC name
O1,O7-Bis{[(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxyoxolan-2-yl]methyl} tetrahydrogen tetraphosphate | |
Other names
P1,P4-Bis(5'-uridyl) tetraphosphate; INS-365; Diquafosol tetrasodium
| |
Identifiers | |
| |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
PubChem CID
|
|
UNII |
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C18H26N4O23P4 | |
Molar mass | 790.306 g·mol−1 |
Pharmacology | |
None | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Diquafosol (tradename Diquas) is a pharmaceutical drug for the treatment of dry eye disease. It was approved for use in Japan in 2010.[1] It is formulated as a 3% ophthalmic solution of the tetrasodium salt.
Its mechanism of action involves agonism of the P2Y2 purinogenic receptor.[2]
{{cite journal}}
: CS1 maint: numeric names: authors list (link)